Study patients had high-grade serous, platinum-resistant ovarian cancer and a median of four prior lines of therapy. Call ...
Share-transfer books are expected to close Nov. 5. Elme plans to move remaining assets to a trust; the trustee sets the ...
Among 459 participants, more with blood in urine saw it resolve on sefaxersen than placebo; blinded follow-up will measure ...
KRAS mutations affect about 40% of colorectal cancers, and G12D is the most common. Genmab will conduct the study; Incyte ...
The 56% response rate came from 25 patients with CEA-high tumors; BeOne intends to advance both lung programs toward ...
PRAME-high melanoma: 12.5-month median response duration; 91% alive at one year. First data on IMA402 with IMA401 in lung cancer are expected in 2027.
At week 12, 60% of patients without prior advanced therapy failure had an endoscopic response, versus 15% on placebo; ...
The analysis included 295 people and found reductions in all four urinary markers, adding evidence FILSPARI may affect ...
SUNS declared a prorated $0.09-per-share fourth-quarter dividend, payable Nov. 5 to holders of record Nov. 2; the merger ...
MakerSpace used 3D scans to give other manufacturers precise measurements for custom parts; auction proceeds will benefit The ...
The first payment has been initiated on an agreement valued at up to $250,000; work includes model refinement, workflow ...
Newport Gold (NWPG) subsidiary NFI Empire announced Rockford Fosgate’s return as official audio partner for its Project ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results